“As a leading tumor specimen provider, Bio-Options required an accurate solution for classifying tumors. Classifying tumors is a tedious, time-consuming process that ties up our highly trained professionals.
We tried mainstream AI models like GPT-4 and Gemini Pro but they fell short and privacy is critical. This is where InteliGems Labs stepped in. Their Launchpad process and AI models quickly advanced us from concept to a pilot customized to our needs.
The results are amazing: $400,000 in annual savings, 80% faster order fulfillment, and a 20% increase in orders. We're excited to explore further AI innovations with InteliGems; they’re an exceptional AI partner.”
Larry Blocher, M.D., J.D.
CEO, Bio-Options